Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
By K. Miller, Molin Wang, J. Gralow, M. Dickler, M. Cobleigh, E. Perez, T. Shenkier, D. Cella, N. Davidson. New England Journal of Medicine, 2007
3,079 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/f2cc33ec9bad2c3add08a3ee08444b67c67bed5d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
In Oncology
Citations in the corpus
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, background): “70) NS No improvement 2 [24]”
- Modes of resistance to anti-angiogenic therapy (2008, background): “aspx?CdrID=39762">paclitaxel extended progression-free survival (but not overall survival”
- An overview of triple-negative breast cancer (2016, background): “VEGF inhibitors block the growth of tumor neovasculature and the anti-VEGF monoclonal antibody, bevacizumab, has been shown to increase response rate (RR) and progression-free survival (PFS) of patients with metastatic breast cancer when added to firstline chemotherapy in various randomized phase II”
- Ten years of anti-vascular endothelial growth factor therapy (2016, result): “…combination with paclitaxel in February 2008 for the treatment of metastatic HER2-negative breast cancer, and, although response rates and PFS were improved compared with paclitaxel alone 94 , subsequent studies, using first-or second-line bevacizumab, reported smaller improvements in PFS 95–97 .”
- Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). (2015, background): “In metastatic TNBC, addition of bevacizumab to once-per-week paclitaxel improves response rates and time to progression.(11,12) Whether the addition of bevacizumab to NACT in TNBC could improve pCR rates and long-term outcomes was unknown.”
- RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. (2011, result): “In the pivotal phase III E2100 trial, when compared with weekly paclitaxel alone, weekly paclitaxel plus BV significantly prolonged progression-free survival (PFS) and increased the objective response rate (ORR), while having limited impact on safety.(11,12) Subsequently, the Avastin Plus Docetaxel ”
- Chemotaxis in cancer (2011, background): “and have been shown to increase the survival of patients with metastatic breast and colorectal cancers when combined with standard chemotherap”
- Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, neutral): “Grade 3 HTN occurred in 1% to 18% of patients (18,19,107,108).”
- Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (2009, result): “BV was well tolerated, and the incidence of targeted AEs in patients with glioblastoma was similar to that observed in previous BV trials.(16-19) The incidence of certain AEs, such as the rate of infection, increased with the addition of chemotherapy; however, no new safety issues related to BV or B”